New answers tagged

2

The key is that TKIs, such as Imatinib, are a therapy rather than a cure Per Wikipedia, Imatinib acts as a competitive inhibitor of the otherwise constitutively-active BCR-ABL fusion protein, rather than the fusion gene. By binding the kinase domain, BCR-ABL is unable to phosphorylate downstream effectors that result in unchecked proliferation. As long as ...


Top 50 recent answers are included